INmune Bio Inc. INMB 深 滬
等待開盤 10-25 09:30:00 美东时间
1.92
+0.130
+7.26%
華盛通- 最 高1.93
- 今 開1.82
- 成交量 30.45万股
- 最 低 1.8106
- 昨 收 1.79
- 總市值 4488.92万
- 52周最高 11.64
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 1.71
- 委 比 -19.72%
- 總股本 2337.98万
- 歷史最高 30.37
- 量 比 1.04
- 振 幅 6.67%
- 歷史最低 1.71
- 每 手 1
- 風險率 2.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, announced that its CEO, David Moss, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, in New York City. Moss will discuss the company's CORDStrom™ platform, which targets Recessive Dystrophic Epidermolysis Bullosa (RDEB), an ultra-rare pediatric disease. The event will include one-on-one meetings and is part of a broader ...
10-14 11:00
INmune Bio Submits Manuscript Detailing Results Of Phase 2 MINDFuL Trial To Nature Portfolio Journal, npj Dementia
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial.
09-29 20:02
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
INmune Bio announced the submission of a manuscript detailing the Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer's disease. While the trial did not meet its primary endpoint in the overall population, it showed promising results in a predefined subgroup (ADi population) with both amyloid pathology and high inflammation, demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints, and indicated no amyloid-r...
09-29 12:00
INmune Bio Completes First Full-Scale Pilot Commercial Manufacturing Run Of CORDStrom, Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Therapy, For Treatment Of RDEB
INmune Bio Inc. (NASDAQ:INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today
09-15 20:10
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
INmune Bio Inc. successfully completed its first full-scale pilot commercial manufacturing run of CORDStrom™, a mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in the UK. This milestone brings the company closer to submitting a Marketing Authorization Application (MAA) in the UK by mid-2026 and a Biologics License Application (BLA) in t...
09-15 12:00
CORRECTION: INmune Bio Q2 Adj. EPS $(0.34) Beats $(0.39) Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 32 percent increase over losses of $(0.50) per share from the same
08-08 06:38
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
INmune Bio's Phase I/II CaRe PC trial of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) met its primary and secondary endpoints, with INKmune™ being well-tolerated and demonstrating an excellent safety profile. Patients with low NK cell activation saw the most significant improvement in biomarkers. INKmune™ converts NK cells into tumor-killing memory-like NK cells, persisting over 100 days and functioning in hypoxic...
08-04 12:00
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
INmune Bio Inc. will host a conference call on August 7, 2025, at 4:30 PM ET to discuss Q2 2025 results and provide a corporate update. The call will be accessible via dial-in numbers or live webcast. The company, focusing on inflammation and immunology, has three product platforms targeting chronic inflammation and cancer. Forward-looking statements involve risks and uncertainties.
07-31 11:00
